Overview of Glimepiride + Metformin Tablets:
INSUGLO-M Tablets are combinations of Glimepiride and Metformin. Glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
- Type 2 diabetes mellitus.
- In diabetic patient whose diabetes is not controlled by monotherapy of metformin.
- Diabetic patients who have initially respond to glimepride alone but require additional glycemic control.
Metformin decreases blood glucose levels by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. These effects are mediated by the initial activation by metformin of AMP-activated protein kinase (AMPK), a liver enzyme that plays an important role in insulin signaling, whole body energy balance, and the metabolism of glucose and fats.